Clonidine and Lemborexant interaction
Clonidine and Lemborexant: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Clonidine (QLONILIK) label · effective 2026-08-12
Avoid use with other central nervous system (CNS) depressants ( 5.3 )
Avoid use with other central nervous system (CNS) depressants, as this combination may cause excessive drowsiness or sedation [see Drug Interactions (7) ].
Intervention Avoid concomitant use of CNS depressants with QLONILIK.
Intervention Monitor blood pressure and heart rate, and adjust dosage of QLONILIK accordingly in patients treated concomitantly with antihypertensives CNS depressants Clinical Implication Concomitant use of CNS depressants with clonidine potentiates the sedating effects [see Warnings and Precautions (5.3) ].
Concomitant use of CNS depressants with clonidine potentiates the sedating effects.
From the Lemborexant (DAYVIGO) label · effective 2025-02-24
Risk increases with dose and use with other central nervous system (CNS) depressants.
Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment.
Complex sleep behaviors may occur following the first or any subsequent use of DAYVIGO, with or without the concomitant use of alcohol and other CNS depressants [see Drug Interactions ( 7.1 )] .
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.